ReviewJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2012
Drug transport across the blood-brain barrier.
Review in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 876 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
876 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,896 citations in OpenAlex.
- The cerebellum in migraine: a narrative review of anatomical, imaging, and clinical evidence.Frontiers in neurology · 2026Pooled it
- Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Impact of High-Dose Rifampicin on Linezolid Pharmacokinetics in Tuberculous Meningitis.Open forum infectious diseases · 2026Trial
- Safety and efficacy of GD-11 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.Stroke and vascular neurology · 2025Trial
- A staged zebrafish-mouse screening strategy for antiseizure compound prioritization.Neuropharmacology · 2026Article
- ASIC1a as an integrating node in ischemic neurotoxicity: crosstalk with NMDAR and TRPM signaling.Pflugers Archiv : European journal of physiology · 2026Review
- Design, synthesis and pharmacological evaluation of novel 2-aryloxazole-based HMolecular diversity · 2026Article
- IDH-genotype-linked kinase rewiring accompanies enhanced therapeutic response to dual-drug ferritin nanocages in high-grade glioma.Materials today. Bio · 2026Article
- Thinking beyond blood: brain concentrations and brain-blood ratios in postmortem toxicology.Journal of analytical toxicology · 2026Article
- Article
- Penetrating potential evaluation of cyclotriphosphazenes target blood-brain barrier via computational toxicology methods.iScience · 2026Article
- The Battle Between Japanese Encephalitis Virus and Host Innate Immune System: Evasion and Response.Viruses · 2026Review
- Pharmacokinetics of Diclazuril in the Plasma and Cerebrospinal Fluid of Healthy Adult Horses After a Single Oral Dose Administered as a Pelleted Topdressing.Journal of veterinary pharmacology and therapeutics · 2026Article
- From Hepatitis to Encephalitis: Neuroinvasion and Antiviral Development in Rift Valley Fever Virus Infection.Pathogens (Basel, Switzerland) · 2026Review
- Review
- Ferroptosis as an immunometabolic checkpoint in brain tumours: spatial vulnerabilities and therapeutic opportunities.Molecular brain · 2026Review
- Synthesis of 4-Hydroxyacetophenone-Derived Bis-Schiff Bases as Potent Cholinesterase Inhibitors: In Vitro Evaluation, Molecular Docking, DFT, and ADMET Analysis.Chemistry & biodiversity · 2026Article
- cGAS-STING axis: A central regulator of neural homeostasis and neuroinflammatory pathogenesis.Neural regeneration research · 2026Article
- Targeted HA@Que-Mn nanozymes alleviate postherpetic neuralgia by modulating neuroinflammation.Materials today. Bio · 2026Article
- Impact of Obstructive Sleep Apnea on Blood-Brain Barrier Permeability and Membrane Proteins.International journal of molecular sciences · 2026Review
816 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The blood-brain barrier (BBB) prevents the brain uptake of most pharmaceuticals. This property arises from the epithelial-like tight junctions within the brain capillary endothelium. The BBB is anatomically and functionally distinct from the blood-cerebrospinal fluid barrier at the choroid plexus. Certain small molecule drugs may cross the BBB via lipid-mediated free diffusion, providing the drug has a molecular weight <400 Da and forms <8 hydrogen bonds. These chemical properties are lacking in the majority of small molecule drugs, and all large molecule drugs. Nevertheless, drugs can be reengineered for BBB transport, based on the knowledge of the endogenous transport systems within the BBB. Small molecule drugs can be synthesized that access carrier-mediated transport (CMT) systems within the BBB. Large molecule drugs can be reengineered with molecular Trojan horse delivery systems to access receptor-mediated transport (RMT) systems within the BBB. Peptide and antisense radiopharmaceuticals are made brain-penetrating with the combined use of RMT-based delivery systems and avidin-biotin technology. Knowledge on the endogenous CMT and RMT systems expressed at the BBB enable new solutions to the problem of BBB drug transport.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.